2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Phase 1 Clinical Trial Starts for RVX-208
RVX only Canadian company to win World Economic Forum award
Dr. Jacques Genest Presents RVX-208 Data at the American Heart Association Conference
RVX Presenting at IAS in Santorini, Greece
Resverlogix Presents Data at DALM Scientific Conference
Stella Thomson Joins RVX Board of Directors
RVX Data Published in Current Opinion in Investigational Drugs
TGF-Beta Shield Potential New Therapy for Glaucoma
Amended Finance - Interest Rate Reduction
Interest Rate Increase
RVX Wins Frost & Sullivan's Excellence in Technology Award
Interest Rate Increase
RVX To Host Live Teleconference
Additional Proof-of-Concept in Non-Human Primates
RVX to Present Data at DALM Conference
Dr. Roger Newton speaks of Resverlogix
Sun Health to Examine RVX's ApoA-l Technology for Alzheimer's
US $25M Bought Deal Closed
RVX to Close US $25M Bought Deal on June 7, 2007
Resverlogix Closes US $25M Bought Deal
Roger Newton, Co-Developer Lipitor(R), Joins RVX Board
Resverlogix Announces Research Advances in Ophthalmology
28 & 42 Day Monkey Data
Webcast/Teleconference Corporate Update
ACC Meeting Highlights Need for ApoA-I
ApoA-I White Paper
Clinical Advisory Board Endorses RVX-208
IND & Microdosing Update
RVX-208 Passes Key Toxicology Milestone
Alzheimer's Research Commences
Drs. Radar and Genest Join RVX Clinical Review Committee
RVX Hires Advisor for Strategic Alternatives
RVX Secures 17M Financing
Convertible Debt Financing